1887

Abstract

This study was carried out to investigate the urinary pharmacokinetics and pharmacodynamics of faropenem administered orally at 5 mg kg in six healthy dogs to assess the efficacy of the drug for canine urinary tract infections (UTIs) with extended-spectrum β-lactamase (ESBL)-producing bacteria. Six strains of ESBL-producing Escherichia coli (ESBL-EC) with the following faropenem minimum inhibitory concentrations (MICs) were used: 1 µg ml (n=2), 2 µg ml (n=2), 4 µg ml (n=1) and 16 µg ml (n=1). Urine samples were obtained every 4 h for the first 12 h after administration to measure urinary drug concentration and urinary bactericidal titres (UBTs). Both the urine concentration of faropenem and the UBTs for all tested strains peaked at 0–4 h after administration, and decreased markedly at 8–12 h. The mean urinary concentration of faropenem at 8–12 h (23±5.2 µg ml) exceeded the MIC of 1 µg ml by fourfold, which is required to inhibit the growth of 90  % of ESBL-EC. These findings indicate that faropenem administered twice daily at a dose of 5 mg kg is acceptable for the treatment of most dogs with ESBL-EC-related UTIs.

Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000004
2019-03-20
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/acmi/1/1/acmi000004.html?itemId=/content/journal/acmi/10.1099/acmi.0.000004&mimeType=html&fmt=ahah

References

  1. Smee N, Loyd K, Grauer GF. UTIs in small animal patients: part 2: diagnosis, treatment, and complications. J Am Anim Hosp Assoc 2013;49:83–94 [CrossRef]
    [Google Scholar]
  2. Ewers C, Grobbel M, Stamm I, Kopp PA, Diehl I et al. Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum-beta-lactamase-producing Escherichia coli among companion animals. J Antimicrob Chemother 2010;65:651–660 [CrossRef]
    [Google Scholar]
  3. Marques C, Belas A, Franco A, Aboim C, Gama LT et al. Increase in antimicrobial resistance and emergence of major international high-risk clonal lineages in dogs and cats with urinary tract infection: 16 year retrospective study. J Antimicrob Chemother 2018;73:377–384 [CrossRef]
    [Google Scholar]
  4. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159–166 [CrossRef]
    [Google Scholar]
  5. Ling GV, Norris CR, Franti CE, Eisele PH, Johnson DL et al. Interrelations of organism prevalence, specimen collection method, and host age, sex, and breed among 8,354 canine urinary tract infections (1969–1995). J Vet Intern Med 2001;15:341–347
    [Google Scholar]
  6. Smee N, Loyd K, Grauer G. UTIs in small animal patients: part 1: etiology and pathogenesis. J Am Anim Hosp Assoc 2013;49:1–7 [CrossRef]
    [Google Scholar]
  7. Shimizu T, Harada K, Tsuyuki Y, Kimura Y, Miyamoto T et al. In vitro efficacy of 16 antimicrobial drugs against a large collection of β-lactamase-producing isolates of extraintestinal pathogenic Escherichia coli from dogs and cats. J Med Microbiol 2017;66:1085–1091 [CrossRef]
    [Google Scholar]
  8. Matsuzaki K, Nishiyama T, Hasegawa M, Kobayashi I, Kaneko A et al. In vitro bactericidal activities of new oral penem, faropenem against the various clinical isolates. Jpn J Antibiot 1999;52:431–438
    [Google Scholar]
  9. Dalhoff A, Nasu T, Okamoto K. Beta-lactamase stability of faropenem. Chemotherapy 2003;49:229–236 [CrossRef]
    [Google Scholar]
  10. Hamilton-Miller JM. Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem. Pharmacotherapy 2003;23:1497–1507 [CrossRef]
    [Google Scholar]
  11. Okamoto M, Ochiai T, Ichiki T. The effects on kidneys of dogs after a single or repeated dosing of faropenem sodium. Jpn Pharmacol Ther 1998;26:13–21
    [Google Scholar]
  12. Faqi AS, Lanphear C, Gill S, Colagiovanni DB. Juvenile toxicity study of faropenem medoxomil in beagle puppies. Reprod Toxicol 2010;30:619–624 [CrossRef]
    [Google Scholar]
  13. Wagenlehner FM, Naber KG. Antibiotic treatment for urinary tract infections: pharmacokinetic/pharmacodynamic principles. Expert Rev Anti Infect Ther 2004;2:923–931 [CrossRef]
    [Google Scholar]
  14. Wagenlehner FM, Wagenlehner C, Redman R, Weidner W, Naber KG. Urinary bactericidal activity of doripenem versus that of levofloxacin in patients with complicated urinary tract infections or pyelonephritis. Antimicrob Agents Chemother 2009;53:1567–1573 [CrossRef]
    [Google Scholar]
  15. Shimizu T, Harada K, Manabe S, Tsukamoto T, Ito N et al. Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling. J Med Microbiol 2017;66:616–621 [CrossRef]
    [Google Scholar]
  16. Food and Drug Administration Guidance for industry, Bioanalytical method validation. 2001;http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf#search=%27Bioanalytical+Method+Validation%2C+Center+for+Drug+Evaluation+and+Research.%27 Jan 15, 2016
  17. Well M, Naber KG, Kinzig-Schippers M, Sörgel F. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. Int J Antimicrob Agents 1998;10:31–38 [CrossRef]
    [Google Scholar]
  18. So W, Crandon JL, Nicolau DP. Effects of urine matrix and pH on the potency of delafloxacin and ciprofloxacin against urogenic Escherichia coli and Klebsiella pneumoniae. J Urol 2015;194:563–570 [CrossRef]
    [Google Scholar]
  19. Monlouis JD, De Jong A, Limet A, Richez P. Plasma pharmacokinetics and urine concentrations of enrofloxacin after oral administration of enrofloxacin in dogs. J Vet Pharmacol Ther 1997;20:61–63
    [Google Scholar]
  20. Daniels JB, Tracy G, Irom SJ, Lakritz J. Fluoroquinolone levels in healthy dog urine following a 20-mg/kg oral dose of enrofloxacin exceed mutant prevention concentration targets against Escherichia coli isolated from canine urinary tract infections. J Vet Pharmacol Ther 2014;37:201–204 [CrossRef]
    [Google Scholar]
  21. Barger A, Fuhst C, Wiedemann B. Pharmacological indices in antibiotic therapy. J Antimicrob Chemother 2003;52:893–898 [CrossRef]
    [Google Scholar]
  22. Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am 2009;23:791–815 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.0.000004
Loading
/content/journal/acmi/10.1099/acmi.0.000004
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error